Lung Disease News and Research

RSS

Middle-aged adults with lung disease may have greater risk of dementia later in life

Middle-aged adults with lung disease may be at greater risk of developing dementia or cognitive impairment later in life, according to new research published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

26 Nov 2018

MERS virus that causes harmless cold in camels can be fatal for humans

What causes only a harmless cold in camels can be fatal for humans: an infection with the MERS virus. Since its discovery in 2012, the virus was detected in approximately 2,000 patients and 36 percent of them have not survived the severe lung disease known as MERS.

22 Nov 2018

Survey: Pulmonologists want more information on inhalation devices for COPD

In an era of personalized medicine, physicians treating patients with chronic obstructive pulmonary disease should consider individualized therapy depending on disease severity and the cost and availability of medications.

20 Nov 2018

Vision impairments may increase risk of falls in older adults

Vision impairment and blindness affect one in 11 Americans age 65 and older. Because our population is aging, the number of older adults with vision problems is predicted to rise.

19 Nov 2018

Hypertonic saline shown to aid breathing in cystic fibrosis babies

The first-ever randomized controlled trial on babies with CF has found that treatment with inhaled hypertonic saline can improve breathing and lung health.

9 Nov 2018

Determine goals of healthcare before making healthcare-related choices

What are the goals of healthcare? That very question must be asked more frequently before healthcare-related choices are made.

7 Nov 2018

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

Slime in showerheads could harbour dangerous lung bacteria finds study

A study has shown that the showerheads contain slime that can be home to potentially dangerous bacteria which lead to severe lung disease. Mycobacterial bacteria are responsible for lung diseases explain experts.

4 Nov 2018

Lymph nodes serve as reservoirs of prolonged bacterial persistence during Mtb infection

Lymph nodes can contain large numbers of tuberculosis-causing bacteria and serve as long-term reservoirs of bacterial persistence, according to a study published November 1 in the open-access journal PLOS Pathogens by JoAnne Flynn of the University of Pittsburgh School of Medicine, and colleagues.

2 Nov 2018

Four mild forms of adenovirus cases at Voorhees Pediatric Facility under control and no new cases reported

Voorhees Pediatric Facility, a pediatric special care nursing facility located in Voorhees, New Jersey, has had four patients with chronic lung disease contract a mild form of adenovirus.

2 Nov 2018

Toxic effects of drugs in the lungs 'more widespread than thought'

A systematic review of research has revealed that the toxic effects on the lung of drugs commonly taken to treat a range of common conditions is much more widespread than thought.

29 Oct 2018

Head and neck cancer survivors more likely to commit suicide

Despite improved survival rates among cancer patients, the risk of death by suicide remains high, especially among those treated for head and neck cancers.

25 Oct 2018

New genetic pathways associated with severe lung disease identified in extremely premature infants

Scientists from Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago and colleagues identified promising new genetic pathways associated with severe lung disease in extremely premature infants, as well as pathways linked to faster recovery from lung disease in this population.

25 Oct 2018

SLU researcher seeks to find solutions for 'chemo brain' symptoms and side effects of opioids

With a pair of RO1 grants from the National Institutes of Health, pain researcher Daniela Salvemini, Ph.D., will embark on two new research projects, studying chemotherapy-induced cognitive impairment, or "chemo brain," symptoms and unwanted side effects of opioids.

23 Oct 2018

Researchers identify common genetic connection in lung conditions

An international research team led by members of the University of Colorado School of Medicine faculty has identified a genetic connection between rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis.

22 Oct 2018

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients.

22 Oct 2018

Veracyte to present data demonstrating potential of Envisia Genomic Classifier to improve ILD diagnosis

Veracyte, Inc. announced the presentation of data demonstrating that the Envisia Genomic Classifier can help physicians more confidently diagnose interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF), without the need for surgery.

8 Oct 2018

Genentech announces Phase III study results of baloxavir marboxil in people at high risk of flu

Genentech, a member of the Roche Group, today announced that the Phase III CAPSTONE-2 study showed treatment with baloxavir marboxil significantly reduced the time to improvement of influenza symptoms versus placebo in people at high risk of serious complications from the flu, which includes adults 65 years of age or older, or those who have conditions such as asthma, chronic lung disease, morbid obesity, or heart disease.

4 Oct 2018

FDA approves manufacturing of Insmed's ARIKAYCE at Therapure Biopharma's Mississauga facility

Therapure Biomanufacturing, an integrated contract development and manufacturing organization and a division of Therapure Biopharma Inc., today announced approval for the manufacturing of Insmed Incorporated's ARIKAYCE® at its Mississauga facility by the U.S. Food and Drug Administration.

3 Oct 2018

Study: Federal Agencies underestimate e-cigarette explosion and burn injuries

Electronic cigarettes (or e-cigarettes) are devices commonly powered by a battery that aerosolize liquid and chemical flavorants.